← All trials
NCT00129129
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2004
- Primary completion
- May 1, 2006
- Completion date
- May 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 756
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
- HibMenCY
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.